Abstract
This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Keywords: Randomized control trials, stroke, rehabilitation
Current Vascular Pharmacology
Title: Randomized Clinical Stroke Trials in 2006
Volume: 6 Issue: 1
Author(s): Meheroz H. Rabadi and John P. Blass
Affiliation:
Keywords: Randomized control trials, stroke, rehabilitation
Abstract: This article reviews randomized control trials (RCTs) published in 2006 of various medications evaluated for stroke patients. These trials were primarily efficacy studies. These included aggrenox (an antiplatelet agent), magnesium (to treat arterial spasm after an aneurysmal subarachnoid hemorrhage), NXY (a free radical trapping agent) and albumin which were both tested as a neuroprotectant, amphetamine (to aid motor recovery), fluoxetine (an anti-depressant and anxiolytic) and low molecular weight heparin (for prevention of deep vein thrombosis post-stroke).
Export Options
About this article
Cite this article as:
Rabadi H. Meheroz and Blass P. John, Randomized Clinical Stroke Trials in 2006, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331259
DOI https://dx.doi.org/10.2174/157016108783331259 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Tako-tsubo Cardiomyopathy: A Review of the Literature
Current Cardiology Reviews Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis
Current Vascular Pharmacology Models to Study Atherosclerosis: A Mechanistic Insight
Current Vascular Pharmacology Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology High-pitch Dual-source CT Angiography before TAVI - the Value of ECG Gating
Current Medical Imaging Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Developmental Current and Future Therapy for Severe Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Therapeutic Potential of Cannabinoids in Trigeminal Neuralgia
Current Drug Targets - CNS & Neurological Disorders Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Neurobiological Influences on Recovery from Traumatic Brain Injury: The Role of Genetic Polymorphisms
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Insights on Aortic Aneurysm)
Current Pharmaceutical Design N-Butyl Cyanoacrylate Embolization of a Peripheral Pulmonary Artery Aneurysm in a Patient with Patent Ductus Arteriosus
Current Cardiology Reviews